SCHEMBL481157

SCHEMBL481157

CCCc1c(SCc2cccc(Cc3cccc(C(=O)OC)c3)c2)ccc(C(C)=O)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
RECQL P46063 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CYP4F2 P78329 2/20 0.42
CYP4A11 Q02928 2/20 0.42
LOXL2 Q9Y4K0 1/20 0.40
CYSLTR1 Q9Y271 3/20 0.40
CYSLTR2 Q9NS75 2/20 0.40
GSK3B P49841 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
SLC7A5 Q01650 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
GRM2 Q14416 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481180 0.89 AR (0.47) NPC1RAB9ASMN1; SMN2CYSLTR1CYSLTR2
SCHEMBL481274 0.84 GRM2 (0.45) SMN1; SMN2LMNACYSLTR1CYSLTR2PPARG
SCHEMBL481143 0.84 CYSLTR1 (0.45) RAB9ASMN1; SMN2CYSLTR1CYSLTR2PPARG
SCHEMBL480793 0.79 CYSLTR1 (0.42) MEN1KMT2ACYP4F2CYP4A11LOXL2
SCHEMBL481156 0.77 CYP4F2 (0.41) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL10740766 0.77 CYSLTR1 (0.60) LMNACYSLTR1CYSLTR2PPARGPPARD
SCHEMBL3227554 0.77 AR (0.48) NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL481053 0.75 GRM2 (0.50) NPC1RAB9ASMN1; SMN2LMNACYSLTR1
SCHEMBL480938 0.74 AR (0.50) NPC1RAB9ASMN1; SMN2LMNAL3MBTL1
SCHEMBL480249 0.72 CYSLTR1 (0.43) CYSLTR1CYSLTR2PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 NPC1 1656/4885RAB9A 2231/4885SMN1; SMN2 4205/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 NPC1 1477/4885RAB9A 3170/4885SMN1; SMN2 3201/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 NPC1 1477/4885RAB9A 3170/4885SMN1; SMN2 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.